ARCHIVES

Letter to the Editors: Burzynski Responds To FDA Release Of Annual Report Data

This article is from The Cancer Letter archive.

Vol. 24 No. 20 | May 22, 1998

Download PDF Visit The Full Archive

Related Articles

ASCO Recommends Aromatase Inhibitors As Adjuvant For Some Breast Cancer

July 30, 2010

Auditor Raymond Weiss Finds “Incredible” Protocol Violations–26% Of Patients Were Ineligible For C225 Study

June 21, 2002

Elderly Patients Fail To Receive New Cancer Therapy For CML

August 27, 2010

Study Section Members Likelier to Be Funded

August 1, 1986

New Compounds To Treat Gleevec-Resistant CML

January 26, 2007

EPO Controversy: ODAC To Review EPO Agents in May; SEC Probes Amgen’s Delay in Study Disclosure.

March 2, 2007